Inhibiting the Mammalian Target of Rapamycin Blocks the Development of Experimental Cerebral Malaria
ABSTRACT Malaria is an infectious disease caused by parasites of several Plasmodium spp. Cerebral malaria (CM) is a common form of severe malaria resulting in nearly 700,000 deaths each year in Africa alone. At present, there is no adjunctive therapy for CM. Although the mechanisms underlying the pa...
Guardado en:
Autores principales: | Emile B. Gordon, Geoffrey T. Hart, Tuan M. Tran, Michael Waisberg, Munir Akkaya, Jeff Skinner, Severin Zinöcker, Mirna Pena, Takele Yazew, Chen-Feng Qi, Louis H. Miller, Susan K. Pierce |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
American Society for Microbiology
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d9d29f731e7d438284e52153462fb045 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Blocking mammalian target of rapamycin (mTOR) improves neuropathic pain evoked by spinal cord injury
por: Wang Xiaoping, et al.
Publicado: (2016) -
SIRT1 negatively regulates the mammalian target of rapamycin.
por: Hiyaa Singhee Ghosh, et al.
Publicado: (2010) -
Prognostic significance and function of mammalian target of rapamycin in tongue squamous cell carcinoma
por: Shau-Hsuan Li, et al.
Publicado: (2017) -
Mammalian malaria: Remembering the Alamo
por: Colin J. Sutherland
Publicado: (2020) -
Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LHBETATAG retinal tumors
por: Y Piña, et al.
Publicado: (2011)